Ceritinib For Lung Cancer Treatment

Quincy Chu, MD, associate professor, medical oncologist, University of Alberta, discusses the development of ceritinib.

Clinical Pearls:

• Ceritinib is a second-generation ALK inhibitor
• In a preclinical setting, ceritinib was found to have activity to the ALK-amplified cell lines as well as in human samples
• Unlike crizotinib, ceritinib does have substantial CNS penetration ​